Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Abogen Biosciences›
News
AddedJul 2, 2026
UpdatedJul 2, 2026
Abogen Biosciences

Abogen Biosciences

Series C+

Abogen Biosciences is a clinical-stage biotechnology company developing mRNA drugs and vaccines for infectious diseases, oncology and autoimmune conditions.

HQ
Suzhou, Jiangsu, CN
Founded
2019
Loading
Overview
Compare
Fundraising
Employees
News
Website

Latest News About Abogen Biosciences

Abogen Biosciences Reports Positive Preliminary FIH Data for ABO2203 mRNA Bispecific T-Cell Engager at AACR 2026

Abogen Biosciences

Abogen Biosciences Reports Positive Preliminary FIH Data for ABO2203 mRNA Bispecific T-Cell Engager at AACR 2026

Preliminary first-in-human data presented for ABO2203 mRNA-encoded CD3xCD19 TCE in relapsed/refractory B-NHL at AACR 2026 oral; also...

Apr 20, 2026

Abogen Biosciences Receives Dual IND Approvals for KRAS mRNA Cancer Vaccine

Abogen Biosciences

Abogen Biosciences Receives Dual IND Approvals for KRAS mRNA Cancer Vaccine

Dual IND China NMPA and US FDA for ABO2102 KRAS mRNA vaccine demonstrating anti-tumor activity; expands oncology pipeline.

Aug 4, 2025

Abogen Biosciences Secures IND Approval for mRNA Shingles Vaccine

Abogen Biosciences

Abogen Biosciences Secures IND Approval for mRNA Shingles Vaccine

IND approved Mar 2025 for Abogen mRNA shingles (VZV) vaccine using proprietary base-modification and structure design platform; part of...

Mar 29, 2025

Abogen Receives IND for Lyophilized mRNA RSV Vaccine

Qiming Venture Partners

Abogen Receives IND for Lyophilized mRNA RSV Vaccine

IND for lyophilized mRNA RSV vaccine using base-modification + self-developed LNP with large-scale Phase 3 validation and China IP; >2...

Jan 1, 2025

Abogen Biosciences Raises Over $700M in Series C for mRNA Trials

Fierce Biotech

Abogen Biosciences Raises Over $700M in Series C for mRNA Trials

Abogen Biosciences closed >$700M Series C to advance ARCoV mRNA vaccine and pipeline in oncology and infectious disease using proprietary...

Aug 19, 2021

Abogen ARCoV mRNA COVID-19 Vaccine First in China Clinical Trials

Abogen Biosciences

Abogen ARCoV mRNA COVID-19 Vaccine First in China Clinical Trials

ARCoV encoding RBD of SARS-CoV-2; first mRNA vaccine approved for clinical trials in China June 2020; Phase 3 with Walvax; lyophilized...

Jan 1, 2021